RxDoctor Payments Data

Sameera Ray

Family · Sun City, AZNPI 1568199826

Payments from drug & device makers

$1,507in general payments, 2019–2025

Across 33 payments — averaging $45.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$749
  • AstraZeneca$139
  • Novocure Inc.$99
  • Progenics Pharmaceuticals, Inc.$76
  • Endo USA, Inc.$66
  • Coloplast$56
  • plus $323 from 11 others

What the payments were for

  • Travel & lodging$60140%
  • Food & beverage$90660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,507 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$25,374
Medicare patients
193
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron111$85,013
MyrbetriqMirabegron92$76,620
JardianceEmpagliflozin11$15,253
Estradiol162$10,557
Solifenacin Succinate112$4,478
Trospium Chloride81$3,246
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst106$1,274
Rosuvastatin Calcium33$1,142
Tamsulosin Hcl72$1,003
Oxybutynin Chloride ErOxybutynin Chloride37$784
Metronidazole22$655
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$583
Cephalexin15$453
Finasteride19$449
Atorvastatin Calcium47$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$55$85,013111 claims
Astellas Pharma US IncMyrbetriq$30$76,62092 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →